Oxford-based Ultromics closed a $55 million Series C round to expand its artificial intelligence platform that spots hidden heart disease in routine scans. The funding comes as hospitals struggle with rising heart failure rates and mounting healthcare costs that could hit $70 billion annually by 2030.
The $30 Billion Heart Failure Crisis
Heart failure affects 64 million people worldwide, yet doctors miss up to 64% of cases with preserved ejection fraction (HFpEF). This diagnostic blind spot creates a deadly problem. Patients walk into hospitals with symptoms but leave without proper treatment.
The economic impact is staggering. Heart failure costs the US healthcare system over $30 billion each year. Without better detection methods, these costs will more than double to $70 billion by 2030.
Ross Upton, Ultromics CEO and founder, explains the core issue: “Hospitals already have the data, they just haven’t had the tools to extract the more subtle diagnostic signals from it.”
AI Finds Heart Disease Doctors Miss
Ultromics developed EchoGo, an FDA-cleared platform that analyzes standard echocardiogram scans with artificial intelligence. The system trains on massive datasets of real-world heart scans to spot patterns human eyes cannot detect.
The technology focuses on two particularly elusive conditions:
- HFpEF (Heart Failure with Preserved Ejection Fraction) – affects millions but shows subtle symptoms
- Cardiac amyloidosis – a progressive disease often mistaken for common heart problems
Clinical trials show impressive results. EchoGo improved HFpEF detection rates by 73.6% compared to standard risk assessment methods. The platform has already analyzed over 430,000 echocardiograms across major hospital systems.
Major Investors Back Heart Health AI
The Series C round attracted heavyweight investors including L&G, Allegis Capital, and Lightrock. Healthcare giants UChicago Medicine and UPMC Enterprises also participated through their venture arms.
“There’s a long-standing blind spot in cardiology where millions of patients with treatable heart failure are missed,” said Victor Westerlind from Allegis Capital. “Ultromics is closing that gap by making it easier for physicians to identify high-risk patients earlier.”
The funding validates growing investor confidence in AI-powered medical diagnostics. Healthcare AI startups raised billions in 2024, with cardiovascular applications leading the charge.
Medicare Reimbursement Drives Hospital Adoption
Ultromics gained a crucial advantage with Medicare reimbursement approval for both inpatient and outpatient use. This removes the main financial barrier preventing hospitals from adopting new diagnostic tools.
The platform integrates directly into existing hospital workflows without requiring new hardware. Doctors simply upload routine echocardiogram scans and receive AI-generated probability scores highlighting patients at high risk for heart failure.
Top-tier medical centers already use the technology, including May Clinic, Northwestern, and University Hospitals Cleveland. These partnerships provide real-world validation and help refine the AI algorithms.
Expanding Beyond Current Heart Conditions
The Series C funding will accelerate Ultromics’ expansion across the United States, particularly in high-prevalence regions like the Midwest. The company plans to build regional clusters of clinical and commercial adoption.
Ultromics will expand its diagnostic pipeline beyond heart failure. The AI platform could potentially identify other cardiovascular conditions that currently escape detection in routine scans.
Recent product launches show this ambition in action. The company received FDA Breakthrough Device clearance for EchoGo Amyloidosis in late 2024, followed by the launch of EchoGo Score in 2025 for enhanced HFpEF diagnosis.
Heart Failure Detection Race Heats Up
Ultromics enters a competitive landscape as healthcare providers search for better diagnostic tools. Other companies developing AI-powered cardiac imaging include Eko Health, which raised $41 million for heart and lung disease detection.
However, Ultromics holds several advantages. The company built its platform in partnership with the NHS and Mayo Clinic, providing access to diverse patient populations. Its focus on echocardiogram analysis also targets the most common heart scan performed worldwide.
The startup’s Oxford University origins provide additional credibility in the academic medical community. This research foundation helps build trust with hospital administrators who must approve new diagnostic technologies.
Early Detection Saves Lives and Costs
Better heart failure detection creates a ripple effect throughout the healthcare system. Patients diagnosed earlier respond better to treatment and require fewer emergency interventions. Hospitals reduce unnecessary testing while improving patient outcomes.
The economic benefits extend beyond healthcare costs. Heart failure patients often require extended time off work and family caregiving support. Earlier diagnosis and treatment help maintain patient productivity and quality of life.
Ultromics positions itself at the intersection of AI innovation and practical healthcare needs. The company’s technology addresses a clear clinical problem while offering a sustainable business model through Medicare reimbursement.
